Algert Global’s Intellia Therapeutics NTLA Stock Holding History

Algert Global’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$832K	Buy	49,200 +27,280	+124%	+$382K	0.01%	995
2026 Q1	$281K	Buy	+21,920	New	+$279K	﹤0.01%	1032
2025 Q1	–	Sell	-69,354	Closed	-$809K	–	1287
2024 Q4	$809K	Buy	69,354 +8,312	+14%	+$130K	0.02%	828
2024 Q3	$1.25M	Sell	61,042 -7,330	-11%	-$169K	0.03%	705
2024 Q2	$1.53M	Buy	68,372 +51,572	+307%	+$1.23M	0.05%	553
2024 Q1	$462K	Buy	16,800 +2,100	+14%	+$58.3K	0.02%	783
2023 Q4	$448K	Buy	+14,700	New	+$422K	0.02%	854
2023 Q2	–	Sell	-23,610	Closed	-$880K	–	1201
2023 Q1	$880K	Buy	+23,610	New	+$926K	0.04%	679
2022 Q3	–	Sell	-14,653	Closed	-$758K	–	1274
2022 Q2	$758K	Buy	14,653 +10,970	+298%	+$557K	0.06%	590
2022 Q1	$268K	Sell	3,683 -2,745	-43%	-$233K	0.02%	975
2021 Q4	$760K	Sell	6,428 -790	-11%	-$99K	0.09%	366
2021 Q3	$968K	Buy	+7,218	New	+$1.09M	0.13%	240

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Algert Global's NTLA Position: Q2 2026 in Review

Algert Global increased its Intellia Therapeutics (NTLA) stake by 124% in Q2 2026, buying an estimated $382K and bringing the position to 49,200 shares worth $832K. The position accounts for 0.01% of the portfolio, ranked #995.

Algert Global first reported a position in NTLA in Q3 2021 and has held it in 12 quarters since. The position peaked at $1.53M in Q2 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Algert Global held 49,200 shares of Intellia Therapeutics worth $832K as of Q2 2026.
Algert Global bought 27,280 Intellia Therapeutics shares in Q2 2026, an estimated $382K.
Intellia Therapeutics made up 0.01% of Algert Global's portfolio in Q2 2026, its #995 holding.
Algert Global first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 12 quarters since.
Algert Global's Intellia Therapeutics position peaked at $1.53M in Q2 2024.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.